Core Insights - The 8th China International Import Expo (CIIE) opened on November 5, 2025, in Shanghai, showcasing Eli Lilly's commitment to the Chinese market with the theme "Innovative Journey, Infinite Future" [1] - Eli Lilly's strategic focus is on addressing China's public health challenges through its competitive product pipeline and deep local integration across the entire industry chain [3] Product Highlights - Eli Lilly's key product on display is Tirzepatide, approved in China for type 2 diabetes, long-term weight management, and obstructive sleep apnea, targeting the large diabetic and obesity population [4] - The company also presented Donanemab, a breakthrough therapy for Alzheimer's disease, which was approved in China shortly after its introduction at last year's expo [4] - Upcoming products include Imlunestrant for breast cancer and Mirikizumab for inflammatory bowel disease, aimed at preparing the market for future approvals [4] Public Awareness Initiatives - Eli Lilly established the "Memory Café" to raise awareness about Alzheimer's disease, addressing the nearly 17 million patients in China and promoting early diagnosis and treatment [5] - The "Body Resistance Decoding Exhibition" was launched to challenge misconceptions about obesity, emphasizing it as a chronic disease, with over 50.7% of Chinese adults classified as overweight or obese [7] Localization Strategy - Eli Lilly's comprehensive strategy in China includes significant investments exceeding 20 billion RMB, transitioning from a product importer to a local contributor in the "Healthy China" initiative [8] - The company plans to enhance its production capabilities with a 1.5 billion RMB investment in its Suzhou factory for diabetes and obesity drug production [10] - A new medical innovation center will be established in Beijing to improve clinical trial efficiency, alongside the announcement of a Shanghai innovation incubator [10]